Michael K. Smith

Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder

Osteoarthritis year in review 2019: epidemiology and therapy

CONSORT 2010 statement: extension to randomised pilot and feasibility trials

Memantine in Moderate-to-Severe Alzheimer's Disease

Bayesian Design of Proof-of-Concept Trials

The future of drug development: advancing clinical trial design

Cancer drug resistance: an evolving paradigm

The Spread of Obesity in a Large Social Network over 32 Years

CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent

Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review

Optimal experimental design for model discrimination.

The JAK/STAT signaling pathway: from bench to clinic

Estimating the Effect of Smoking Cessation on Weight Gain: An Instrumental Variable Approach

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

Radiomics: the bridge between medical imaging and personalized medicine

A tutorial on Gaussian process regression: Modelling, exploring, and exploiting functions

Statistical challenges in assessing potential efficacy of complex interventions in pilot or feasibility studies

The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

Prescribed drugs containing nitrogen heterocycles: an overview

The effects of ketoconazole on ziprasidone pharmacokinetics —a placebo‐controlled crossover study in healthy volunteers

Implementation of a Bayesian adaptive design in a proof of concept study

VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial

A Quantitative Approach for Making Go/No-Go Decisions in Drug Development

Importance of protocols for simulation studies in clinical drug development

Simulation-based sequential Bayesian design

Statistical Issues in Drug Research and Development.

Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial